Corporate News

2022

Polarean notes statement from Amphion Innovations

25 September 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

2021

Polarean notes statement from Amphion Innovations

25 September 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

2020

Polarean notes statement from Amphion Innovations

25 September 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

2019

Polarean notes statement from Amphion Innovations

25 September 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

2018

Polarean notes statement from Amphion Innovations

25 September 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender").

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Investor Alert

Sign up for Email Alerts